The incidence of venous thromboembolism (VTE) in patients with oncogene-addicted non–small-cell lung cancer (NSCLC) is still in need of further investigation. In this study, we demonstrated a higher incidence of VTE in patients with advanced ROS1-rearranged NSCLC, which was 3- to 5-fold higher compared with the general population with NSCLC. Our results suggest that the molecular profile of NSCLC should be incorporated into a risk-stratification tool and decision-making algorithm for VTE diagnosis and prophylaxis.
Chiari R., Ricciuti B., Landi L., Morelli A.M., Delmonte A., Spitaleri G., et al. (2020). ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). CLINICAL LUNG CANCER, 21(1), 15-20 [10.1016/j.cllc.2019.06.012].
ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)
Chiari R.;Ricciuti B.;Delmonte A.;Spitaleri G.;Lamberti G.Formal Analysis
;Chella A.;Bonanno L.;Galetta D.;
2020
Abstract
The incidence of venous thromboembolism (VTE) in patients with oncogene-addicted non–small-cell lung cancer (NSCLC) is still in need of further investigation. In this study, we demonstrated a higher incidence of VTE in patients with advanced ROS1-rearranged NSCLC, which was 3- to 5-fold higher compared with the general population with NSCLC. Our results suggest that the molecular profile of NSCLC should be incorporated into a risk-stratification tool and decision-making algorithm for VTE diagnosis and prophylaxis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
